AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union

-    PRODUODOPA® is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of advanced Parkinson's disease
-   PRODUODOPA demonstrated sustained...

Related Keywords

Italy ,Australia ,Russia ,Canada ,United Kingdom ,Netherlands ,Sweden ,Belgium ,Japan ,Denmark ,Spain ,Germany ,United States ,Josefa Domingos ,Parkinson Europe ,Angelo Antonini ,Roopal Thakkar ,Foslevodopa Foscarbidopa ,Linkedin ,Parkinson Foundation ,Exchange Commission ,Facebook ,University Of Padua ,Youtube ,Twitter ,Department Of Neuroscience ,European Union ,Instagram ,Regulatory Affairs ,Decentralized Procedure ,Senior Vice President ,Chief Medical Officer ,Lancet Neurology ,Science Direct ,Important Treatment ,Dopamine Dysregulation Syndrome ,Neuroleptic Malignant Syndrome ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Accessed November ,Efficacy Results From ,Markets ,